Exploring teledermatology in managing common inflammatory skin conditions: a systematic review

Year 2024, Volume: 7 Issue: 3, 341 - 345, 27.05.2024

Şule Gençoğlu

https://doi.org/10.32322/jhsm.1469966

Abstract

This investigation delves into the advancing domain of telemedicine within dermatology, highlighting its potential to reshape forthcoming healthcare paradigms. Specifically focusing on the utilization of teledermatology for prevalent inflammatory skin conditions, this study synthesizes literature comprising meta-analyses, comprehensive reviews, editor correspondences, real-world investigations, case collections, and detailed reports. Adhering to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) standards, manuscript selection and data extraction were meticulously executed. Initially, 121 relevant records were identified through database surveys. Following screening, 110 articles met the criteria for in-depth evaluation, with 92 articles ultimately included in our comprehensive review. Teledermatology, bolstered by the exigencies of the pandemic, emerges as a viable alternative for dermatological consultations in the foreseeable future. The rapid uptake and refinement observed during the crisis underscore its potential for further substantive advancements. Nonetheless, the establishment of structured guidelines governing its implementation and ongoing refinement remains imperative.

Keywords

Teledermatology, Inflammatory skin conditions, telemedicine, healthcare dynamics, pandemic adaptation

References

• Megna M, Potestio L, Battista T, et al. Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics. Clin Exp Dermatol. 2022; 47(12):2310-2312.
• Frühauf J, Schwantzer G, Ambros-Rudolph CM, et al. Pilot study on the acceptance of mobile teledermatology for the home monitoring of high-need patients with psoriasis. Australas J Dermatol. 2012;53(1):41-46.
• Julie ZY, Reynolds RV, Olbricht SM, McGee JS. Moving forward with teledermatology: Operational challenges of a hybrid in-person and virtual practice. Clin Dermatol. 2021;39(4):707-709.
• Ferwerda M, Van Beugen S, Van Burik A, et al. What patients think about E-health: patients’ perspective on internet-based cognitive behavioral treatment for patients with rheumatoid arthritis and psoriasis. Clin Rheumatol. 2013;32(6):869-873.
• Schmid-Grendelmeier P, Takaoka R, Ahogo K, et al. Position statement on atopic dermatitis in sub-Saharan Africa: current status and roadmap. J Eur Acad Dermatol Venereol. 2019; 33(11):2019-2028.
• Izquierdo-Domínguez A, Rojas-Lechuga MJ, Alobid I. Management of allergic diseases during COVID-19 outbreak. Curr Allergy Asthma Rep. 2021;21(2):8.
• Armstrong AW, Chambers CJ, Maverakis E, et al. Effectiveness of online vs. in-person care for adults with psoriasis: a randomized clinical trial. JAMA Netw Open. 2018;1(6):e183062.
• Martora F, Picone V, Fabbrocini G, Marasca C. Hidradenitis suppurativa flares following COVID-19 vaccination: a case series. JAAD Case Rep. 2022;23:42-45.
• Alexander H, Patel NP. Response to Martora et al.’s “Hidradenitis suppurativa flares following COVID-19 vaccination: a case series”. JAAD Case Rep. 2022;25:13-14.
• Ruggiero A, Martora F, Picone V, Marano L, Fabbrocini G, Marasca C. Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review. Biomedicines. 2022;10(2):455.
• Salvador-Rodriguez L, Montero-Vílchez T, Arias-Santiago S, Molina-Leyva A. Paradoxical hidradenitis suppurativa in patients receiving TNF-α inhibitors: case series, systematic review, and case meta-analysis. Dermatol. 2020;236(4):307-313.
• Martora MMF, Megna M, Battista T, Potestio L. Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience. Clin Cosmet Investig Dermatol. 2023;16:135-148.
• Ford AR, Gibbons CM, Torres J, et al. Access to dermatological care with an innovative online model for psoriasis management: results from a randomized controlled trial. Telemed J E Health. 2019;25(7):619-627.
• Haque W, Chandy R, Ahmadzada M, Rao B. Teledermatology after COVID-19: key challenges ahead. Dermatol Online J. 2021; 27(4):13030/qt5xr0n44p.
• Choi E, Mak WK, Law JY, Santos D, Quek SC. Optimizing teledermatology: looking beyond the COVID-19 pandemic. Int J Dermatol. 2021;60(1):119-121.
• Picone V, Martora F, Fabbrocini G, Marano L. “Covid arm”: abnormal side effect after Moderna COVID-19 vaccine. Dermatol Ther. 2022;35(1):e15197.
• McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46-55.
• Martora F, Picone V, Fornaro L, Fabbrocini G, Marasca C. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? J Med Virol. 2022;94(4):1292-1293.
• Shin SH, Hong JK, Hong SA, Li K, Yoo KH. Pityriasis rosea shortly after mRNA-1273 COVID-19 vaccination. Int J Infect Dis. 2022;114:88-89.
• Veraldi S, Spigariolo CB. Pityriasis rosea and COVID-19. J Med Virol. 2021;93(7):4068.
• Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series. Dermatol Ther. 2022;35(2):e15225.
• Martora F, Villani A, Marasca C, Fabbrocini G, Potestio L. Skin reaction after SARS-CoV-2 vaccines reply to ‘cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience’. J Eur Acad Dermatol Venereol. 2023; 37(1):e43-e44.
• Avallone G, Cavallo F, Astrua C, et al. Cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience. J Eur Acad Dermatol Venereol. 2022; 36(11):e876-e879.
• Martora F, Fabbrocini G, Nappa P, Megna M. Impact of the COVID-19 pandemic on hospital admissions of patients with rare diseases: an experience of a Southern Italy referral center. Int J Dermatol. 2022;61(7):e237-e238.
• Martora F, Fabbrocini G, Nappa P, Megna M. Reply to ‘Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2’ by Solimani et al. J Eur Acad Dermatol Venereol. 2022;36(10):e750-e751.
• Solimani F, Mansour Y, Didona D, Dilling A, Ghoreschi K, Meier K. Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2. J Eur Acad Dermatol Venereol. 2021;35(10):e649-e651.
• Falcinelli F, Lamberti A, Cota C, Rubegni P, Cinotti E. Reply to ‘Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2’ by Solimani F et al. J Eur Acad Dermatol Venereol. 2022;36(12):e976-e978.
• Martora F, Villani A, Battista T, Fabbrocini G, Potestio L. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2023;22(1):32-33.
• Washrawirul C, Triwatcharikorn J, Phannajit J, Ullman M, Susantitaphong P, Rerknimitr P. Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2022;36(11):1947-1968.
• Qaderi K, Golezar MH, Mardani A, et al. Cutaneous adverse reactions of COVID-19 vaccines: a systematic review. Dermatol Ther. 2022;35(5):e15391.
• Kazi R, Evankovich MR, Liu R, et al. Utilization of asynchronous and synchronous teledermatology in a large health care system during the COVID-19 pandemic. Telemedicine and e-Health. 2021;27(7): 771-777.
• Ruggiero A, Martora F, Fornaro F, Scalvenzi M, Fabbrocini G, Villani A. Reply to ‘Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity’ by R. Molinier, et al. J Eur Acad Dermatol Venereol. 2023; 37(2):e130-e131.
• Molinier R, Roger A, Genet B, et al. Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity. J Eur Acad Dermatol Venereol. 2022;36(3):e164-e166.
• Pasquali P, Sonthalia S, Moreno-Ramirez D, et al. Teledermatology and its current perspective. Indian Dermatol Online J. 2020;11(1):12-20.
• Ruggiero A, Martora F, Fabbrocini G, et al. The role of teledermatology during the COVID-19 pandemic: a narrative review. Clin Cosmet Investig Dermatol. 2022;15:2785-2793.
• Ruggiero A, Megna M, Fabbrocini G, Martora F. Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clin Exp Dermatol. 2022;47(10):1863-1864.
• Stadler PC, Senner S, Frey S, et al. Teledermatology in times of COVID-19. J Dermatol. 2021;48(5):620-624.
• Martora F, Marasca C, Battista T, Fabbrocini G, Ruggiero A. Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: ‘Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa’. Clin Exp Dermatol. 2022;47(11):2026-2028.
• Ruggiero A, Martora F, Fornaro L, et al. The impact of COVID-19 pandemic on nonmelanoma skin cancers: report of a Southern Italy referral centre. Clin Exp Dermatol. 2022;47(11):2024-2025.